Go Deep
Jubilant Pharmova Limited
Jubilant Pharmova Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,821 | 45.1 | 2.23 | 0.51 | 1,000.00 |
| Oct 2026 | 22,238 | 45.1 | 2.23 | 0.51 | 1,000.00 |
| Oct 2026 | 22,128 | 42.0 | 2.08 | 0.51 | 931.90 |
Jubilant Pharmova Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 22,211,000,000.0 | 22,722,000,000.0 | 21,161,000,000.0 | 18,789,000,000.0 |
| Net Profit | 565,000,000.0 | 1,194,000,000.0 | 559,000,000.0 | 1,029,000,000.0 |
| EPS | 3.6 | 7.5 | 3.5 | 6.5 |
Jubilant Pharmova Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 82,251,000,000.0 | 71,921,000,000.0 | 66,448,000,000.0 | 62,193,000,000.0 | — |
| Net Profit | 3,985,000,000.0 | 8,394,000,000.0 | 771,000,000.0 | -610,000,000.0 | — |
| EPS | 25.1 | 53.0 | 4.9 | -3.8 | — |
Jubilant Pharmova Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 155,227,000,000.0 | 127,564,000,000.0 | 115,485,000,000.0 | 111,567,000,000.0 | — |
| Total Liabilities | 84,271,000,000.0 | 65,178,000,000.0 | 61,274,000,000.0 | 57,649,000,000.0 | — |
| Total Equity | 70,928,000,000.0 | 62,549,000,000.0 | 54,339,000,000.0 | 53,993,000,000.0 | — |
Owes vs Owns
Jubilant Pharmova Limited owed ₹0.54 for every ₹1 it owned in Mar 2026, up from ₹0.52 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.54× | 0.51× | 0.53× | 0.52× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Jubilant Pharmova Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 8.3%Receivables 6.9%Inventory 7.9%Fixed assets (tangible) 44.6%Intangible assets 26.4%Other assets 5.9%
How it's funded — Mar 2026
Short-term debt 1.6%Long-term debt 19.1%Payables 8.0%Other liabilities 25.6%Shareholders' equity 45.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,282.6 | 1,098.6 | 962.6 | 1,015.2 |
| Receivables | 1,069.6 | 891.5 | 915.9 | 961.2 |
| Inventory | 1,231.5 | 1,129.2 | 1,289.6 | 1,380.5 |
| Fixed assets (tangible) | 6,921.5 | 5,179.3 | 3,841.2 | 3,463.3 |
| Intangible assets | 4,102.7 | 3,637.7 | 3,507.2 | 3,379.6 |
| Long-term investments | 0.8 | 7.5 | 7.8 | 223.6 |
| Other assets | 914.0 | 812.6 | 1,024.2 | 733.3 |
| Liabilities & equity | ||||
| Short-term debt | 247.8 | 286.6 | 247.0 | 299.7 |
| Long-term debt | 2,971.7 | 2,150.3 | 3,167.1 | 3,110.4 |
| Payables | 1,234.1 | 1,004.8 | 856.3 | 821.3 |
| Other liabilities | 3,973.5 | 3,076.1 | 1,857.0 | 1,533.5 |
| Shareholders' equity | 7,095.6 | 6,238.6 | 5,421.1 | 5,391.8 |
| Net tangible assets | 2,990.1 | 2,617.2 | 1,926.7 | 2,019.7 |
Jubilant Pharmova Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 12,268,000,000.0 | 10,721,000,000.0 | 9,713,000,000.0 | 6,607,000,000.0 | — |
| Investing Activities | -12,600,000,000.0 | 4,877,000,000.0 | -6,079,000,000.0 | -5,444,000,000.0 | — |
| Financing Activities | 949,000,000.0 | -14,527,000,000.0 | -4,325,000,000.0 | -1,567,000,000.0 | — |